← Back to Search
Risk Factors For Doxorubicin-induced Congestive Heart Failure.
D. V. Von Hoff, M. Layard, P. Basa, H. L. Davis, A. L. Von Hoff, M. Rozencweig, F. Muggia
Published 1979 · Medicine
Download PDFAnalyze on Scholarcy
Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through retrospective analysis of 4018 patient records. The overall incidence of drug-induced congestive heart failure was 2.2% (88 cases). The probability of incurring doxorubicin-induced congestive heart failure was related to the total dose of doxorubicin administered. There was a continuum of increasing risk as the cumulative amount of administered drug increased. A weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule. An increase in drug-related congestive heart failure was also seen with advancing patient age. Performance status, sex, race, and tumor type were not risk factors. These data will enable clinicians to better estimate the risk/benefit ratio in individual patients receiving prolonged administration of doxorubicin. They also provide a basis for the investigation of less cardiotoxic anthracycline analogues or for designing measures to prevent doxorubicin-induced cardiomyopathy.
This paper references
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.
C. Myers (1977)
QRS voltage change with adriamycin administration.
R. A. Minow (1978)
Phase I clinical study of quelamycin.
A. Brugarolas (1978)
Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin‐D and mithramycin
J. Kushner (1975)
A phase I II study of rubidazone in patients with solid tumors
R. Benjamin (1977)
Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
R. Hutchinson (1978)
Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy.
J. Singer (1978)
Age-related adriamycin cardiotoxicity in children.
C. Pratt (1978)
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
D. V. Von Hoff (1977)
A new antitumor antibiotic, carminomycin (NSC-180024).
Gause Gf (1974)
Adriamycin cardiotoxicity in man.
J. Rinehart (1974)
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
C. Tan (1973)
Adriamycin cardiotoxicity in children. Case reports, literature review, and risk factors
M. Prout (1977)
Adriamycin. A new anticancer drug with significant clinical activity.
R. Blum (1974)
Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule
R. Benjamin (1974)
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
R. A. Minow (1975)
Measuring the Risk of Coronary Heart Disease in Adult Population Groups: II. Coronary Heart Disease in the Framingham Study
Thomas R. Dawber (1957)
Evaluation of cardiac function during adriamycin therapy
J. Burg (1974)
Noninvasive cardiac evaluation of patients receiving adriamycin.
G. Ewy (1978)
Adriamycin cardiomyopathy—risk factors
R. A. Minow (1977)
Analysis of Survival Data under the Proportional Hazards Model
N. Breslow (1975)
Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
M. Billingham (1977)
High incidence of cardiomyopathy in children treated with adriamycin and DTIC in combination chemotherapy.
P. Smith (1977)
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
Time relationship between last dose of daunorubicin and congestive heart failure.
F. Cavalli (1977)
The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma
D. Karnofsky (1948)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
Adriamycin and radiation: synegistic cardiotoxicity.
J. Merrill (1975)
Anthracycline cardiomyopathy monitored by morphologic changes.
M. Billingham (1978)
Systolic time intervals in monitoring adriamycin-induced cardiotoxicity.
S. Balcerzak (1978)
Subclinical adriamycin cardiotoxicity: detection by timing the arterial sounds.
G. Fa (1978)
Phase II evaluation of adriamycin in human neoplasia
R. O'bryan (1973)
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.
M. Bristow (1978)
Doxorubicin cardiotoxicity: role of digoxin in prevention.
C. Williams (1978)
Covariance analysis of censored survival data.
N. Breslow (1974)
A phase I II study of adriamycin DNA complex (A DNA)
R. Benjamin (1977)
Echocardiography in adriamycin cardiotoxicity
K. R. Bloom (1978)
Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.
A. Weiss (1976)
Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
A. Buzdar (1978)
Echocardiographic evaluation of adriamycin cardiotoxicity in children.
A. Ramos (1976)
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
This paper is referenced by
Amelioration of Doxorubicin Induced Cardiotoxicity in Tumor Bearing Mice by Ferulic Acid: a Mechanistic Study at Cellular and Biochemical Level
Saratchandran A. Divakaran (2012)
Review Article Cardiomyopathy Associated With Cancer Therapy
Anthony F. Yu (2014)
Classification by Mechanisms of Cardiotoxicity
Dwight Kerkhove (2017)
Doxorubicin-Induced Cardiotoxicity: Molecular Mechanism and Protection by Conventional Drugs and Natural Products
Hayder M. Al-kuraishy (2017)
Prevalence Of Anthracycline Induced Cardiomyopathy Amongst Cancer Patients Treated At Kenyatta National Hospital
Caroline N Tonio (2018)
Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2.
P. Spallarossa (2009)
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
M. Hensley (1999)
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
M. Hussein (2002)
Cardiac profiles of liposomal anthracyclines
M. Theodoulou (2004)
26 Drug-Induced Cardiomyopathies
J. Klimas (2012)
Disruption of endothelial cell intraflagellar transport protein 88 exacerbates doxorubicin-induced cardiotoxicity.
Vincent Z Luu (2020)
Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline
M. Maruzzo (2016)
A study of assessing cardiotoxicity by MUGA technique in patients treated for carcinoma breast
Bukya Sheela (2016)
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
K. N. Timm (2020)
Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity.
A. Abushouk (2017)
Heart Transplantation and Left Ventricular Assist Devices in Cancer Survivors
E. Kransdorf (2017)
Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation
B. Aleman (2014)
Chapter 7 – Cardiovascular System
P. Greaves (2012)
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Сибирского отделения Российской академии медицинских наук, Кемерово, Россия
S. Ivanov (2013)
Natural Product Research: Formerly Natural Product Letters
F. Giampieri (2014)
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines
A. Barac (2016)
Cardiotoxicity after Adjuvant Anthracycline-based Chemotherapy and Radiotherapy for Breast Cancer
T. Yau (2005)
Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome.
Y. Sadzuka (2002)
Liposome-encapsulated doxorubicin is less cardiotoxic than conventional doxorubicin for metastatic breast cancer
C. Shapiro (2002)
Concomitant Impairment of Left Ventricular Systolic and Diastolic Function During Doxorubicin Therapy: A Prospective Radionuclide Ventriculographic and Echocardiographic Study
T. Nousiainen (2002)
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. F. Broeyer (2008)
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II
J. Sparano (2009)
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
R. Soloman (2008)
Early breast cancer therapy and cardiovascular injury.
L. Jones (2007)
A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy
A. Sandler (2004)
The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction
V. Dolinsky (2017)
Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines.
L. Lanzarini (2000)See more